| Biomarker ID | 1495 |
| PMID | 25115396 |
| Year | 2014 |
| Biomarker | mir-27b |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Decreased in patients with shorter progression free interval |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 0.255 (95% CI: 0.069-0.944) |
| Effect on Pathways | Pathway include: synapse; nuclear chromosome; DNA-binding transcription factor activity, RNA polymerase II-specific; nuclear chromatin; presynapse |
| Experiment | Progression Vs No Progression |
| Type of Biomarker | Prognostic |
| Cohort | 49 tissues with Prostate cancer and 41 non cancerous tissues were chosen for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.0346 |
| Method Used | RT-qPCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |